line

R&D

Innovative Science Affordable Medicine

Our Technology

line
WMBIO has a unique business model called ‘Optimal Pathway’.
Based on clinical information from Asan Medical Center and know-how in predictive
biomarker development, we can shorten the lead time and increase the possibility of
making a new, successful drug.

By developing certain groups of patient’s
predictive biomarker we can diagnose, and predict drug
response and monitor disease progress in cancer research

Development of field

Biomarker: Development, validation, and efficacy analysis of predictive
biomarker based on actual patient’s clinical information

Chemical drug: Development of next generation personalized novel drugs
based on biomarker

Biologics: Development of a targeted therapeutic antibody for medical unmet
needs and overcoming resistance of existing anti-cancer drugs